Clinical trial
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
NCT00486031 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00486031 |
|---|---|
| Title | Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study |
| Official title | A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Inflammatory Bowel Disease, Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Balsalazide Disodium |
| Enrollment | 443 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 13, 2007 |
| Last update posted | Aug 15, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: